. 2011 Apr 13;26(5):843–850. doi: 10.1111/j.1440-1746.2010.06605.x

Table 1.

Laboratory findings in 70 chronic hepatitis C virus (HCV) 4a patients treated with peg interferon plus Ribavirin therapy

	Sustained virological responders (SVR) (n = 31)	Non‐responders (NR) (n = 39)
Age (years)	37.7 ± 9.9	41.51 ± 18.87
Sex (female/male)	5/26	11/28
BMI (kg/m²)	34.17 ± 4.45	31.1 ± 6.73
Baseline alanine aminotransferase (IU/L)	34 ± 23.8	45.9 ± 32.5
Alpha fetoprotein level (ng/mL)	3.5 ± 1.9	9.35 ± 13.49
HCV RNA	3.97 × 105 ± 6.47 × 105	4.77 × 105 ± 9.1 × 105
level (copies/mL)	3.97 × 105 ± 6.47 × 105	4.77 × 105 ± 9.1 × 105
Histological stage
F(0–1)	26/31	5/39
F(2–4)	5/31	34/39
A(0–1)	25/31	21/39
A(2–4)	6/31	18/39

The univariate analysis of clinical and virological factors was compared in NR versus SVR patients. Data of this table showed that AFP levels were significantly higher in NR patients than SVR patients (P = 0.014). Also, lower stages of liver fibrosis (F0–F1) were associated with a higher probability of achieving sustained response (P = 0.0001).

P‐value < 0.05 considered statistically significant.